This Article Full Text Full Text (PDF) All Versions of this Article: 1078-0432.CCR-07-1186v1 13/23/7139    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Orita, H. Articles by Gabrielson, E. Search for Related Content PubMed PubMed Citation Articles by Orita, H. Articles by Gabrielson, E.

Selective Inhibition of Fatty Acid Synthase for Lung Cancer Treatment

Authors' Affiliations: ¹ Department of Pathology and Johns Hopkins Cancer Center, Johns Hopkins University School of Medicine; and ² FASgen, Inc., Baltimore, Maryland

Requests for reprints: Edward Gabrielson, Department of Pathology, Johns Hopkins Cancer Center, CRB2/Room 304, 1550 East Orleans Street, Baltimore, MD 21231. Phone: 410-502-5250; Fax: 410-502-7943; E-mail: egabriel{at}jhmi.edu.

Purpose: Fatty acid synthase (FAS) is overexpressed in many human cancers and is considered to be a promising target for therapy. However, in vitro use of previous generations of FAS inhibitors has been limited by severe, but reversible, anorexia in treated animals, which is thought to be related to a parallel stimulation of fatty acid oxidation by these agents. This study investigated pharmacologic inhibition of FAS using C93, a rationally designed molecule that inhibits FAS activity without affecting fatty acid oxidation in preclinical models of lung cancer.

Experimental Design: Activity of C93 on FAS and fatty acid oxidation was evaluated in cultured non–small cell lung cancer (NSCLC) cells. Antineoplastic activity of the compound, given orally or by i.p. injection, was evaluated in s.c. and orthotopic NSCLC xenografts.

Results: Our experiments confirm that C93 effectively inhibits FAS without stimulating fatty acid oxidation in lung cancer cells. More importantly, C93 significantly inhibits the growth of both s.c. and orthotopic xenograft tumors from human NSCLC cell lines without causing anorexia and weight loss in the treated animals.

Conclusions: We conclude that inhibition of FAS can be achieved without parallel stimulation of fatty acid oxidation and that inhibition of tumor growth in vivo can be achieved without anorexia and weight loss. Thus, this therapeutic strategy holds promise for clinical treatment of cancers, including non–small cell lung cancer, the leading cause of cancer mortality in the United States and Europe.

This article has been cited by other articles:

				L. M. Knowles, C. Yang, A. Osterman, and J. W. Smith Inhibition of Fatty-acid Synthase Induces Caspase-8-mediated Tumor Cell Apoptosis by Up-regulating DDIT4 J. Biol. Chem., November 14, 2008; 283(46): 31378 - 31384. [Abstract] [Full Text] [PDF]

				T. Maier, M. Leibundgut, and N. Ban The Crystal Structure of a Mammalian Fatty Acid Synthase Science, September 5, 2008; 321(5894): 1315 - 1322. [Abstract] [Full Text] [PDF]

				H. Orita, J. Coulter, E. Tully, F. P. Kuhajda, and E. Gabrielson Inhibiting Fatty Acid Synthase for Chemoprevention of Chemically Induced Lung Tumors Clin. Cancer Res., April 15, 2008; 14(8): 2458 - 2464. [Abstract] [Full Text] [PDF]